Categories

26-Sep-2019

September 2019 Shareholder Newsletter

Kazia Therapeutics is pleased to make its September 2019 newsletter available to investors.

13-Sep-2019

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award

Kazia has been named as a winner in the 2019 Australian and New Zealand Leadership Forum (ANZLF) Trans-Tasman Innovation & Growth Awards.

06-Sep-2019

Dr James Garner presents at the 2019 Gold Coast Investment Showcase

Our CEO, Dr James Garner recently presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase.

22-Aug-2019

Dr James Garner featured in The Australian Financial Review

Our Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.

27-Jun-2019

Dr James Garner provides comprehensive GDC-0084 update to Morgans

Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on our ongoing trials for our lead candidate, GDC-0084.

26-Jun-2019

Media coverage of DIPG researcher, Professor Matt Dun for World Brain Tumour Day

Professor Matt Dun was interviewed across leading broadcast and print media about his research into DIPG, a rare but aggressive form of childhood brain cancer.

24-Jun-2019

June 2019 Shareholder Newsletter

Kazia Therapeutics is pleased to make its June 2019 newsletter available to investors.

11-Jun-2019

World Brain Tumour Day: Enhancing awareness of the devastating childhood brain cancer, DIPG

Dr Matt Dun, a leading cancer researcher, discusses his research into Diffuse Intrinsic Pontine Glioma (DIPG) and GDC-0084.

28-May-2019

Dr James Garner discusses ground-breaking Alliance study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media in Sydney to discuss Kazia’s participation in the ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.

08-May-2019

Dr James Garner discusses Kazia’s Phase 2 trial in glioblastoma with Proactive Investors

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the release of new safety and tolerability data from the company’s phase IIa trial of GDC-0084 in newly-diagnosed brain cancer patients.

08-May-2019

Kazia calls for greater awareness of one of the deadliest women’s cancers worldwide

This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of one of the deadliest women’s cancers worldwide.

02-Apr-2019

Proactive Investors speaks with Kazia CEO Dr James Garner

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the presentation of new data from the company’s Cantrixil trial in ovarian cancer at the American Association of Cancer Research (AACR) 2019 Annual Meeting on April 1.

25-Mar-2019

Kazia to present on Cantrixil at AACR 2019 meeting

Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) has been selected to present data from the Phase I study of Cantrixil in ovarian cancer at the American Association for Cancer Research (AACR) 2019 Annual Meeting.  AACR is one of the top-tier academic conferences worldwide and will be held from 29 March to 3 April at the Georgia World Congress Center in Atlanta, Georgia, USA.

14-Feb-2019

February 2019 Shareholder Newsletter

Kazia Therapeutics is pleased to make its February 2019 newsletter available to investors.

13-Feb-2019

Dr Alan Olivero discusses what makes a good brain cancer drug

Dr Alan Olivero, who led the team at Genentech that developed GDC-0084, discusses what makes a good brain cancer drug.

11-Jan-2019

Proactive Investors speaks with Kazia CEO Dr James Garner

Our CEO, Dr James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco last week to discuss the multiple data readouts rapidly approaching for our GDC-0084 and Cantrixil clinical trial programs.

12-Nov-2018

2018 Annual General Meeting Presentation Webcast

Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to invite investors to view an archived copy of CEO, Dr James Garner’s address from the company’s 2018 AGM, together with questions and answers relating to the presentation.

05-Nov-2018

November 2018 Shareholder Newsletter

Kazia Therapeutics is pleased to make its November 2018 newsletter available.

31-Oct-2018

Morgans interview with Kazia CEO Dr James Garner

Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.

24-Oct-2018

Potential glioblastoma therapy GDC-0084 presented to Finance News Network audience

Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.